Lam S, Becker H D
Department of Medicine, University of British Columbia, Vancouver, Canada.
Chest Surg Clin N Am. 1996 May;6(2):363-80.
Although the exact proportion of patients with carcinoma in situ in whom disease will progress to invasive lung cancer is not known, and although there have been reports that some individuals may continue to show malignant cells in sputum for several years without symptoms or abnormality on chest radiograph, untreated or suboptimally treated carcinoma in situ has been shown to progress to invasive cancer or metastatic disease. A study by Frost and co-workers showed that cancer developed in approximately 10% of individuals with moderate atypia and 40% of those with severe atypia in sputum cytology. Therefore, the proportion of individuals with carcinoma in situ in whom invasive cancer will develop is likely to be greater than 40%. Lung cancer is almost uniformly fatal when untreated, and, if the disease is allowed to progress to the invasive stage, the results of currently available therapy are poor. A lesson must be learned from cervical cancer screening. As has been shown by Anderson and co-workers, if individuals harboring dysplasia or carcinoma in situ are actively sought for and treated by laser or cryotherapy, the incidence and mortality of invasive cervical cancer can be reduced to extremely low levels. If current work directed toward detecting early lung cancer in sputum cytology specimens in high-risk groups using quantitative image cytometry or molecular markers is successful, the ability to localize small preinvasive lesions with fluorescence bronchoscopy will become even more important for the pulmonologist or thoracic surgeon. Endoscopic ultrasound can be used to determine the depth of tumor infiltration into the bronchial wall or adjacent structures. Biopsy of mediastinal and peribronchial lymph nodes can be performed under sonographic guidance for more accurate staging. By coupling sensitive diagnostic tools to new treatment modalities, such as chemoprevention and various endobronchial therapies, it is hoped that the traditionally poor prognosis for patients with lung cancer can be altered in the near future.
尽管尚不清楚原位癌患者中疾病进展为浸润性肺癌的确切比例,尽管有报告称一些人可能在数年内痰中持续出现恶性细胞,而胸部X线片却无任何症状或异常,但未经治疗或治疗不充分的原位癌已被证实会进展为浸润性癌或转移性疾病。弗罗斯特及其同事进行的一项研究表明,痰细胞学检查显示,中度异型增生患者中约10%会发生癌症,重度异型增生患者中这一比例为40%。因此,原位癌患者中发生浸润性癌的比例可能大于40%。肺癌若不治疗几乎必然致命,而且如果疾病进展到浸润阶段,目前可用治疗方法的效果也很差。必须从宫颈癌筛查中吸取教训。正如安德森及其同事所表明的,如果积极寻找患有发育异常或原位癌的个体并采用激光或冷冻疗法进行治疗,浸润性宫颈癌的发病率和死亡率可降至极低水平。如果目前利用定量图像细胞术或分子标志物在高危人群的痰细胞学标本中检测早期肺癌的工作取得成功,那么对于肺科医生或胸外科医生而言,利用荧光支气管镜定位微小浸润前病变的能力将变得更加重要。内镜超声可用于确定肿瘤浸润支气管壁或邻近结构的深度。可在超声引导下对纵隔和支气管周围淋巴结进行活检,以实现更准确的分期。通过将敏感的诊断工具与化学预防和各种支气管内治疗等新的治疗方式相结合,有望在不久的将来改变肺癌患者传统上较差的预后。